Evidence map›Paper›PMID 27006717›Full record

ArticleThe open cardiovascular medicine journal2015

Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.

Kostas Archontogeorgis, Evangelia Nena, Nikolaos Papanas, Maria Xanthoudaki, Olga Hatzizisi, Georgios Kyriazis, Venetia Tsara, Efstratios Maltezos, Marios Froudarakis, Paschalis Steiropoulos

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The open cardiovascular medicine journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kostas ArchontogeorgisDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Evangelia NenaLaboratory of Hygiene and Environmental Protection, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Nikolaos PapanasSecond Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Maria XanthoudakiDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Olga HatzizisiDepartment of Pneumonology, General Hospital "G. Papanikolaou", Thessaloniki, Greece.
Georgios KyriazisDepartment of Pneumonology, General Hospital "G. Papanikolaou", Thessaloniki, Greece.
Venetia TsaraDepartment of Pneumonology, General Hospital "G. Papanikolaou", Thessaloniki, Greece.
Efstratios MaltezosSecond Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Marios FroudarakisDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Paschalis SteiropoulosDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Democritus University of Thrace · GRG. Papanikolaou General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimHypoxia, a major feature of obstructive sleep apnea (OSA), modifies Vascular Endothelial Growth Factor (VEGF) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) levels, which contribute to atherogenesis and occurrence of cardiovascular (CV) events. We assessed and compared serum levels of VEGF and IGFBP-3 in newly diagnosed OSA patients and controls, to explore associations with anthropometric and sleep parameters and to study the effect of continuous positive airway pressure (CPAP) treatment on these levels. MATERIALS AND

methodsSerum levels of VEGF and IGFBP-3 were measured in 65 OSA patients and 31 age- and body mass index- matched controls. In OSA patients, measurements were repeated after 6 months of CPAP therapy. All participants were non-smokers, without any comorbidities or systemic medication use.

resultsAt baseline, serum VEGF levels in OSA patients were higher compared with controls (p<0.001), while IGFBP-3 levels were lower (1.41±0.56 vs. 1.61±0.38 μg/ml, p=0.039). VEGF levels correlated with apnea-hypopnea index (r=0.336, p=0.001) and oxygen desaturation index (r=0.282, p=0.007). After 6 months on CPAP treatment, VEGF levels decreased in OSA patients (p<0.001), while IGFBP-3 levels increased (p<0.001).

conclusionIn newly diagnosed OSA patients, serum levels of VEGF are elevated, while IGFBP-3 levels are low. After 6 months of CPAP treatment these levels change. These results may reflect an increased CV risk in untreated OSA patients, which is ameliorated after CPAP therapy.

Indexed as

Continuous positive airway pressurehypoxiainsulin-like growth factor binding protein-3obstructive sleep apneatreatment.vascular endothelial growth factor

Identifiers

PMID27006717
PMCPMC4768659
OpenAlexW2200639653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.